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Summary Dermal dendrocytes (DDs) are dendritic cells that exhibit immunoreactivity for factor
XIIIa, and are frequently found in conjunction with basal cell carcinomas (BCCs).
Imiquimod was applied to 12 superficial BCCs every 3 days for 8 weeks. One week after
completion of treatment, seven lesions appeared to have resolved, while five displayed
evidence of residual BCC. Prior to initiation of treatment, the seven imiquimod-
responsive BCCs were surrounded by numerous DDs, whereas the five imiquimod-
resistant BCCs had fewer DDs next to them at the time of entry into the study. It
appears that the pretreatment density in DDs may affect the efficacy of imiquimod in
eradicating skin tumours.
Introduction
The stroma of malignant neoplasms consists of a
heterogeneous cell population of varied embryological
origin. In the past, many of these cells were considered
to be of mesenchymal origin, belonging to the connect-
ive tissue component of the organs, and generally called
fibroblasts. However, the fibroblast-like cells of the skin
represent different cell lineages, showing distinct phe-
notypes that may be explored by immunohistochemis-
try. Among these cells, dermal dendrocytes (DDs) are
dendritic cells exhibiting immunoreactivity for factor
XIIIa (FXIIa), many of which belong to the monocyte–
macrophage lineage. They are frequently found in
conjunction with basal cell carcinomas (BCCs).
Dermal dendrocytes (DDs) are heterogeneous as
regards immunophenotype, stage of maturation and
function. They express different markers at specific
stages of differentiation, and they alter their shape
according to the influences of the extracellular matrix
and neighbouring cells. DDs are involved in a series of
specific functions, and interact with FXIII, which is a
critical transglutaminase in homeostasis of the connect-
ive tissue and in its repair processes.1
The immunomodulator imiquimod enhances the
release of a series of endogenous cytokines by cells
present in the skin, particularly those of the monocyte–
macrophage lineage.2,3 Dermal dendrocytes (DDs)
might play a pivotal role in this mechanism.4,5 Imiqui-
mod has shown efficacy in the treatment of superficial
BCC.6 As with viral condylomas,4 the therapeutic
success might be related to the presence of a cuff of
DD abutted to the base of the neoplasm.
Case report
Twelve superficial BCC were diagnosed on the face of
patients aged from 56 to 68 years. Topical applica-
tions of imiquimod were applied at 3-day intervals for
8 weeks. On clinical and dermoscopic examinations
1 week after completion of treatment, seven lesions
appeared to have resolved, and five showed evidence
of residual BCC. The treated skin fields were erythe-
matous and discretely scaly. Punch biopsies were
performed before treatment and 9 weeks after its
initiation. Sections were prepared for immunohisto-
chemistry using a polyclonal antibody to FXIIIa in
order to identify DDs. Comparisons were made
between the imiquimod-responsive and -resistant
lesions.
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The seven imiquimod-responsive BCCs were surroun-
ded by numerous DDs (median: 153 ⁄ mm2) before
initiation of the treatment (Fig. 1a,b). Complete cure
of these lesions was confirmed histologically. The site of
neoplastic regression was loaded with numerous DDs
(Fig. 2a,b), which were clustered in the superficial
dermis, with a few scattered in the mid-epidermis, in a
location where Langerhans cells are usually found.
The five imiquimod-resistant BCC had fewer DDs
(median 81 ⁄ mm2) abutted to them at entry into the
study. The DD numerical density was modified little
after treatment in the dermis at the site of residual BCC.
Discussion
Host–tumour interactions clearly influence the ultimate
behaviour and prognosis of malignancies. Besides the
crucial role of the immune response, the tumour stroma
with various cytokines and enzymes is involved in the
control of tumour growth, regression and metastatic
progression.7,8 The mode of action of stromal cells
remains controversial and enigmatic. Indeed, several
lines of evidence suggest that the stroma may display
both stimulatory and restrictive effects upon tumour
progression.9–12 The presence of DDs in malignant
cutaneous neoplasms has been of increasing interest
during the past decade.12–15 Given the histogenetic
diversity of the cell types expressing FXIIIa, ranging
from bone-marrow to mesenchyme-derived cells, several
specific cellular functions may be involved in cutaneous
cancers. In particular, they may produce a variety of
cytokines, such as tumour necrosis factor-a,16 which
may operate through a paracrine mechanism upon
other stromal cells and the malignant lineage.7–9
Similarly to the wound-healing process, the peritumo-
ural stroma is probably enriched in cytokines, growth
factors, metalloproteinases and their inhibitors.17 Var-
iations in the resulting molecular interplay may result
in effects as distinct as tumoral progression or regres-
sion.
Extravascular fibrin deposits are frequently present
within and around neoplasms. They are involved in
various aspect of tumour growth. Some tumour-associ-
ated macrophages belong to the DD population. They
are present in areas of fibrin deposition in some
neoplasms. This situation strongly suggests that FXIIIa
is involved in the stabilization of the intratumural fibrin
network that facilitates tumour–matrix relationships
and tumour angiogenesis. FXIIIa-positive DDs prevail
over all other cell types at the site of intratumoral fibrin
deposits in different malignancies, and are strongly
attached to the fibrin network. FXIII probably plays a
significant role in fibrin stabilization and consequently
has an effect on tumour progression.
The present observation is in line with previous
findings,3–5 suggesting that the pretreatment density in
dermal DDs may affect the efficacy of imiquimod in
eradicating skin tumours. It is therefore suggested that
in cases of imiquimod treatment failure, combination
with another agent in order to boost DDs might be
beneficial. As such, topical retinoids, a-hydroxyacids
and b-lipohydroxyacid are compounds that could be
useful, although they may increase the risk of more
severe local skin reactions.
(a) (b)
Figure 1 Superficial basal cell carcinoma
before imiquimod treatment. The neo-
plasm is underlined by a dense population
of factor XIIIa-positive dendrocytes. Ori-
ginal magnification: (a) · 80, (b) · 160.
(a) (b)
Figure 2 After 8 weeks of imiquimod
treatment, the basal cell carcinoma has
completely regressed. The density in factor
XIIIa-positive dendrocytes is high in the
superficial dermis. Similar cells are scat-
tered in the epidermis. Original magnifi-
cation: (a) · 80, (b) · 160.
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